Shonali Midha, MD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses a study which evaluated determinants of response and resistance to BCMA-directed bispecific antibodies in patients with multiple myeloma, highlighting the impact of CD4 and CD8 T-cell populations prior to treatment. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.